Skip to main content

Table 2 Baseline characteristics renal cell carcinoma† fisher’s exact test (reported as frequency (percent))

From: Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

 

Clinical benefit (n=2)

No clinical benefit (n=11)

p-value

Age

47.0 (40.0)

53.0 (46.0-54.0)

.641*

Male

2 (100%)

8 (72.7%)

1.0

Baseline ALC

1.55 (1.30)

1.40 (0.80-1.70)

.641*

LDH

277.5 (158.0)

209.0 (151.0-286.0)

.641*

Prior Treatments

1/2 (50%)

6/11 (54.5%)

1.0

Metastatic Subsets

 

Distant Nodes

1 (50%)

2 (18.1%)

.423

Lung +/− Distant Nodes

0

5 (45.5%)

.487

Visceral

1 (50%)

4 (36.4%)

1.0

  1. *Mann–Whitney U (reported as median (interquartile range)).
  2. ALC: Absolute Lymphocyte Count.
  3. LDH: Lactate Dehydrogenase.